Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791919 | 0.93 | PRKCA (0.45) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL394957 | 0.90 | PRKCA (0.54) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL13936815 | 0.89 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL13936814 | 0.88 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL4829981 | 0.87 | PRKCA (0.47) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL13936816 | 0.87 | PRKCA (0.57) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL14435458 | 0.87 | PRKCA (0.49) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL14253803 | 0.85 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL14253800 | 0.85 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL13936821 | 0.85 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885NR1I2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.